Tarcocimab for Diabetic Retinopathy
(GLOW2 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with DR.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, it does mention that participants should not have received certain eye treatments in the past year.
Who Is on the Research Team?
Pablo Velazquez-Martin, MD
Principal Investigator
Kodiak Sciences Inc
Are You a Good Fit for This Trial?
This trial is for people with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) who have type 1 or type 2 diabetes with an HbA1c of ≤12%. Participants should not have had previous intravitreal treatments for DR or DME, and must be able to delay certain retina treatments for at least 6 months. They also need good enough vision as defined by specific eye tests.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive tarcocimab 5 mg or sham treatment via intravitreal injection at Day 1, Week 4, Week 8, Week 20, and Week 44
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Tarcocimab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Kodiak Sciences Inc
Lead Sponsor